|
2019 Conference Publication Uncovering microtubule-driven mechanisms of melanoma invasionJu, R. J., Chhabra, Y., Haass, N. and Stehbens, S. J. (2019). Uncovering microtubule-driven mechanisms of melanoma invasion. 46th Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung (ADF), Munich Germany, Mar 13-16, 2019. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2018 Journal Article Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancerPacker, Leisl M., Stehbens, Samantha J., Bonazzi, Vanessa F., Gunter, Jennifer H., Ju, Robert J., Ward, Micheal, Gartside, Michael G., Byron, Sara A. and Pollock, Pamela M. (2018). Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer. Molecular Oncology, 13 (4), 738-756. doi: 10.1002/1878-0261.12422 |
|
2018 Journal Article The role of melanoma cell-stroma interaction in cell motility, invasion, and metastasisJu, Robert J., Stehbens, Samantha J. and Haass, Nikolas K. (2018). The role of melanoma cell-stroma interaction in cell motility, invasion, and metastasis. Frontiers in Medicine, 5 (NOV) 307, 1-9. doi: 10.3389/fmed.2018.00307 |
|
2018 Journal Article FGFR2b activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancerStehbens, Samantha J., Ju, Robert J., Adams, Mark N., Perry, Samuel, Haass, Nikolas K., Bryant, David M. and Pollock, Pamela M. (2018). FGFR2b activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer. Journal of Cell Science, 131 (15) jcs.213678, 1-16. doi: 10.1242/jcs.213678 |
|
2017 Journal Article PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2mutant endometrial cancersPacker, Leisl M., Geng, Xinyan, Bonazzi, Vanessa F., Ju, Robert J., Mahon, Clare E., Cummings, Margaret C., Stephenson, Sally-Anne and Pollock, Pamela M. (2017). PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2mutant endometrial cancers. Molecular Cancer Therapeutics, 16 (4), 637-648. doi: 10.1158/1535-7163.MCT-16-0415 |
